IHE Overview

Tariffs on Imported Drugs: The U.S. will impose a 15% tariff on drugs imported from countries with which it has tariff deals, including the European Union, South Korea, Japan, and the UK, with larger pharmaceutical companies facing duties in 120 days and smaller ones in 60 days.

Executive Order by President Trump: President Trump signed an executive order imposing a 100% tariff on imported patented pharmaceuticals and active pharmaceutical ingredients, citing national security concerns over reliance on foreign supply chains.

Impact on Pharmaceutical Production: The U.S. currently produces only 15% of the active pharmaceutical ingredients used in patented medicines, with 53% of finished products being imported, prompting the administration to seek increased domestic manufacturing.

Strategies for Companies: Companies can avoid tariffs by committing to onshore production or signing drug pricing agreements with the Department of Health and Human Services, with those meeting these criteria exempt from tariffs until January 20, 2029.

Pharmaceutical Tariffs: Pharmaceutical companies from the EU, Japan, South Korea, Switzerland, and the UK will face separate tariff rates under bilateral deals with the U.S., with potential new tariffs announced as early as Thursday, possibly reaching up to 100% on certain drugs.

Exemptions for Generic Drugs: The new tariffs will not apply to generic drugs, which will be exempt from any additional tariffs, allowing companies to avoid these costs if they relocate manufacturing to the U.S. or negotiate deals with the Trump administration.

Major Pharmaceutical Agreements: Several major pharmaceutical companies have already struck deals with the Trump administration to lower drug prices for American patients, including agreements from companies like Eli Lilly and Pfizer.

Market Reactions: As of the time of reporting, major pharmaceutical ETFs were down about 1%, reflecting market sentiment amid the impending tariff announcements and ongoing negotiations regarding drug pricing.

FDA's Concerns: FDA Commissioner Marty Makary has urged the Trump administration to collaborate with the pharmaceutical industry to address multiple bottlenecks that have caused the U.S. to lag behind China in drug development and clinical trials.

China's Advancements: China is now conducting more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals, highlighting a significant shift in the pharmaceutical landscape.

Reform Recommendations: Makary has called for reforms to streamline the process for starting trials on new treatments, emphasizing the need for the U.S. to improve its drug approval system to deliver more effective treatments to the American public.

FDA Initiatives: The FDA has initiated a program to expedite the review of certain drug applications, aiming to reduce assessment time from the standard 10-12 months to 1-2 months, although challenges remain as some applications continue to be rejected.

Impact of Drug Pricing Deals: Big pharmaceutical companies are negotiating with the U.S. government to lower Medicaid drug prices, but analysts believe the financial impact on these companies may be less severe than initially feared.

Medicaid's Role in Drug Pricing: Medicaid accounts for about 10% of U.S. prescription drug spending and often secures significant discounts, which helps mitigate concerns over pricing pressures on pharmaceutical companies.

Resilience of Health Care ETFs: Diversified health care ETFs, such as the Health Care Select Sector SPDR Fund and Vanguard Health Care ETF, are performing well and provide a buffer against potential volatility from drug pricing news.

Pharma-Specific ETFs and Diversification: While specialized pharmaceutical ETFs may face more direct impacts from pricing negotiations, their diversified structures help reduce risks associated with individual companies, allowing them to remain stable amidst market fluctuations.

ETF Performance: The Amplify Transformational Data Sharing ETF is underperforming, down approximately 3.3% in Monday afternoon trading.

Weakest Components: Notable declines among its components include Cleanspark, which fell by about 13.3%, and Hut 8, which decreased by about 10.1%.

Market Context: The article provides insights into the performance of specific ETFs and their components, reflecting broader market trends.

Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.

ETF Performance: The iShares U.S. Pharmaceuticals ETF is underperforming, down approximately 0.9% in Friday afternoon trading.

Weakest Components: Key contributors to the ETF's decline include Eli Lilly and Phibro Animal Health, both down about 2.4% on the day.

Market Context: The article provides insights into the performance of specific ETFs and their components, reflecting broader market trends.

Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.